PMID- 28128763
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20170310
IS  - 1875-869X (Electronic)
IS  - 1093-2607 (Linking)
VI  - 24
IP  - 3-4
DP  - 2016
TI  - The effect of Intravenous Immunoglobulin (IVIG) on \textitex vivo activation of 
      human leukocytes.
PG  - 39-44
LID - 10.3233/HAB-160293 [doi]
AB  - INTRODUCTION: Intravenous immunoglobulin (IVIG) has been widely used to treat 
      various conditions, including inflammatory and autoimmune diseases. IVIG has been 
      shown to have a direct influence on neutrophils, eosinophils and lymphocytes. 
      However, many aspects IVIG's effect on neutrophils activation still remain 
      unknown. OBJECTIVE: To evaluate the effect of IVIG on PMA-induced activation of 
      neutrophils, with and without priming with TNF-alpha, in a series of in vitro 
      experiments performed on whole blood. RESULTS: Our data coincided with well-known 
      literature indicating that the effect of phorbol 12-myristate 13-acetate (PMA) on 
      human leukocytes includes activation of neutrophils, monocytes and eosinophils, 
      increase of chemiluminescence (CL) and induction of netosis, resulting in 
      assembly of traps. In presence of IVIG (10 mg/mL), CL was reduced by 25% in 
      response to PMA compared to PMA-induced leukocyte activation without IVIG. 
      Decreasing IVIG concentration to 1 mg/mL and below did not inhibit PMA-induced 
      activation of CL.PMA-induced activation after TNF-alpha priming resulted in 
      approximately 50% increase of amplitude of CL response to PMA. Moreover, maximum 
      CL was reached by minute 5, which was more rapid than in the absence of 
      TNF-alpha-priming (in this case maximum CL was reached by minute 15).The IVIG 
      concentrations did not affect morphological changes of leukocytes after 
      sequential addition of TNF-alpha and PMA. IVIG had no effect on leukocyte content and 
      on PMA-induced CL of primed leukocytes.Addition of IVIG under TNF-alpha priming 
      significantly increased the number of traps in the smears in response to PMA 
      activation. Of note, such an increase in the number of traps was depended on the 
      IVIG concentration in plasma. CONCLUSION: In conclusion, we suggest that IVIG is 
      able to reduce the degradation of traps under priming with TNF-alpha. Moreover, IVIG 
      might switch the activation of primed leukocytes to netosis.
FAU - Basyreva, Liliya Yu
AU  - Basyreva LY
AD  - Federal Research and Clinical Center of Physical-Chemical Medicine of Federal 
      Medical Biological Agency, Moscow, Russia.
FAU - Brodsky, Ilya B
AU  - Brodsky IB
AD  - Federal Research and Clinical Center of Physical-Chemical Medicine of Federal 
      Medical Biological Agency, Moscow, Russia.
FAU - Gusev, Alexander A
AU  - Gusev AA
AD  - Federal Research and Clinical Center of Physical-Chemical Medicine of Federal 
      Medical Biological Agency, Moscow, Russia.
FAU - Zhapparova, Olga N
AU  - Zhapparova ON
AD  - Federal Research and Clinical Center of Physical-Chemical Medicine of Federal 
      Medical Biological Agency, Moscow, Russia.
FAU - Mikhalchik, Elena V
AU  - Mikhalchik EV
AD  - Federal Research and Clinical Center of Physical-Chemical Medicine of Federal 
      Medical Biological Agency, Moscow, Russia.
FAU - Gusev, Sergey A
AU  - Gusev SA
AD  - Federal Research and Clinical Center of Physical-Chemical Medicine of Federal 
      Medical Biological Agency, Moscow, Russia.
FAU - Shor, Dana Ben-Ami
AU  - Shor DB
AD  - Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty 
      of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
AD  - Department of Gastroenterology, Sheba Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Dahan, Shani
AU  - Dahan S
AD  - Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty 
      of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Blank, Miri
AU  - Blank M
AD  - Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty 
      of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
AD  - Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty 
      of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Hum Antibodies
JT  - Human antibodies
JID - 9711270
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Dose-Response Relationship, Immunologic
MH  - Extracellular Traps/drug effects/immunology
MH  - Healthy Volunteers
MH  - Humans
MH  - Immunoglobulins, Intravenous/*pharmacology
MH  - Leukocytes/cytology/*drug effects/immunology
MH  - Luminescent Measurements
MH  - Lymphocyte Activation/drug effects
MH  - Primary Cell Culture
MH  - Tetradecanoylphorbol Acetate/*pharmacology
MH  - Tumor Necrosis Factor-alpha/*pharmacology
OTO - NOTNLM
OT  - Intravenous Immunoglobulin (IVIG)
OT  - TNF-alpha
OT  - autoimmunity
OT  - leukocytes
OT  - neutrophils
OT  - priming
EDAT- 2017/01/28 06:00
MHDA- 2017/03/11 06:00
CRDT- 2017/01/28 06:00
PHST- 2017/01/28 06:00 [entrez]
PHST- 2017/01/28 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - HAB293 [pii]
AID - 10.3233/HAB-160293 [doi]
PST - ppublish
SO  - Hum Antibodies. 2016;24(3-4):39-44. doi: 10.3233/HAB-160293.